Controlled clinical trial comparing flurbiprofen and phenylbutazone in patients with rheumatoid arthritis.
Preliminary results in 12 patients with rheumatoid arthritis are presented from an on-going double-blind, between patient comparison of flurbiprofen and phenylbutazone. Patients received either 300 mg flurbiprofen daily or 400 mg phenylbutazone daily over a 2-week treatment period. Two patients treated with phenylbutazone developed a rash, and treatment was discontinued in 1 of them after Day 2.
D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005480:Flurbiprofen / Q000627:therapeutic use*; D006801:Humans; D010653:Phenylbutazone / Q000627:therapeutic use*; D011422:Propionates / Q000627:therapeutic use*
D011422:Propionates; D005480:Flurbiprofen; D010653:Phenylbutazone